Literature DB >> 8064227

Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.

A Wright1, S L Morrison.   

Abstract

Immunoglobulin G (IgG) molecules are glycosylated in CH2 at Asn297; the N-linked carbohydrates attached there have been shown to contribute to antibody (Ab) stability and various effector functions. The carbohydrate attached to the IgG constant region is a complex biantennary structure. Alterations in the structure of oligosaccharide have been associated with human diseases such as rheumatoid arthritis and osteoarthritis. To study the effects of altered carbohydrate structure on Ab effector function, we have used gene transfection techniques to produce mouse-human chimeric IgG1 Abs in the Chinese hamster ovary (CHO) cell line Lec 1, which is incapable of processing the high-mannose intermediate through the terminal glycosylation steps. We also produced IgG1 Abs in Pro-5, the wild-type CHO cell line that is the parent of Lec 1. The Pro-5-produced Ab (IgG1-Pro-5) was similar to IgG1-My 1, a myeloma-produced IgG1 Ab of the same specificity, in its biologic properties such as serum half-life, ability to effect complement-mediated cytolysis, and affinity for Fc gamma RI. Although the Lec 1-produced Ab, IgG1-Lec 1, was properly assembled and retained antigen specificity, it was incapable of complement-mediated hemolysis and was substantially deficient in complement consumption, C1q binding, and C1 activation. IgG1-Lec 1 also showed reduced but significant affinity for Fc gamma R1 receptors. The in vivo half-life of IgG1-Lec 1 was shorter than that of either the myeloma- or Pro-5-produced counterpart, with more being cleared during the alpha-phase and with more rapid clearance during the beta-phase. Clearance of IgG1-Lec 1 could be inhibited by the administration of yeast-derived mannan. Thus the uptake of IgG1-Lec 1 appears to be accelerated by the presence of terminally mannosylated oligosaccharide. Therefore, certain Ab functions as well as the in vivo fate of the protein are dramatically affected by altered carbohydrate structure. Expression of Igs in cell lines with defined glycosylation mutations is shown to be a useful technique for investigating the contribution of carbohydrate structure to Ab function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8064227      PMCID: PMC2191655          DOI: 10.1084/jem.180.3.1087

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  43 in total

1.  Role of the carbohydrate residues of human chorionic gonadotropin in binding and stimulation of adenosine 3',5'-monophosphate accumulation by porcine granulosa cells.

Authors:  C P Channing; C N Sakai; O P Bahl
Journal:  Endocrinology       Date:  1978-08       Impact factor: 4.736

2.  The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G.

Authors:  B J Sutton; D C Phillips
Journal:  Biochem Soc Trans       Date:  1983-04       Impact factor: 5.407

Review 3.  Glycosylation mutants of animal cells.

Authors:  P Stanley
Journal:  Annu Rev Genet       Date:  1984       Impact factor: 16.830

4.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution.

Authors:  J Deisenhofer
Journal:  Biochemistry       Date:  1981-04-28       Impact factor: 3.162

5.  Carbohydrate-mediated clearance of immune complexes from the circulation. A role for galactose residues in the hepatic uptake of IgG-antigen complexes.

Authors:  R W Thornburg; J F Day; J W Baynes; S R Thorpe
Journal:  J Biol Chem       Date:  1980-07-25       Impact factor: 5.157

6.  Biological significance of carbohydrate chains on monoclonal antibodies.

Authors:  M Nose; H Wigzell
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

7.  Complementation between mutants of CHO cells resistant to a variety of plant lectins.

Authors:  P Stanley; L Siminovitch
Journal:  Somatic Cell Genet       Date:  1977-07

8.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Authors:  S L Morrison; M J Johnson; L A Herzenberg; V T Oi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

9.  Structural and numerical variations of the carbohydrate moiety of immunoglobulin G.

Authors:  T Mizuochi; T Taniguchi; A Shimizu; A Kobata
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

10.  Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG.

Authors:  R B Parekh; R A Dwek; B J Sutton; D L Fernandes; A Leung; D Stanworth; T W Rademacher; T Mizuochi; T Taniguchi; K Matsuta
Journal:  Nature       Date:  1985 Aug 1-7       Impact factor: 49.962

View more
  46 in total

Review 1.  Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes.

Authors:  Mattias Collin; Arne Olsén
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

2.  Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Hannah Joerissen; Beate Müller-Tiemann; Heiner Apeler; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

Review 3.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

4.  Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis.

Authors:  Altan Ercan; Jing Cui; Dereck E W Chatterton; Kevin D Deane; Melissa M Hazen; William Brintnell; Colin I O'Donnell; Lezlie A Derber; Michael E Weinblatt; Nancy A Shadick; David A Bell; Ewa Cairns; Daniel H Solomon; V Michael Holers; Pauline M Rudd; David M Lee
Journal:  Arthritis Rheum       Date:  2010-08

5.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

6.  Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.

Authors:  N M Valenzuela; K R Trinh; A Mulder; S L Morrison; E F Reed
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

7.  Immunoglobulin G1 Fc domain motions: implications for Fc engineering.

Authors:  Martin Frank; Ross C Walker; William N Lanzilotta; James H Prestegard; Adam W Barb
Journal:  J Mol Biol       Date:  2014-02-09       Impact factor: 5.469

Review 8.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

9.  Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.

Authors:  Nirmal K Banda; Allyson K Wood; Kazue Takahashi; Brandt Levitt; Pauline M Rudd; Louise Royle; Jodie L Abrahams; Gregory L Stahl; V Michael Holers; William P Arend
Journal:  Arthritis Rheum       Date:  2008-10

10.  Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation.

Authors:  M M Harmsen; C B van Solt; H P D Fijten
Journal:  Appl Microbiol Biotechnol       Date:  2009-05-12       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.